We’re thrilled to head to Barcelona, Spain, from March 11 to 14 for the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026), the world’s premier forum where medicine meets innovation.
As clinicians, device manufacturers, and digital health companies gather to bridge the gap in diabetes care, Glooko is proud to be at the center of the conversation at booth 10 showcasing how our diabetes and glycemic management company is expanding the boundaries of digital health across the full continuum of care.
This year’s focus on AI-driven glucose prediction, smart insulin delivery, and next-generation artificial pancreas systems aligns with our mission to transform diabetes and glycemic care by simplifying workflows and providing care teams with the data-driven insights and technologies needed to improve patient outcomes.
Here’s what you’ll experience at our ATTD 2026 booth:
- Glooko’s SSO and EHR Integrations: The Glooko diabetes management platform can be fully integrated into existing clinical workflows through its single sign-on (SSO) feature and EHR interoperability. Designed to streamline administrative workloads, these capabilities eliminate manual data entry and “password fatigue,” allowing healthcare providers to launch patient profiles, sync reports directly within their existing EHR systems, and prioritize patient care.
- New Glooko Clinic Dashboard: Glooko’s new population health tool, available in select countries, helps clinics manage large diabetes populations by prioritizing patients based on clinical risk and analyzing engagement gaps. Our clinic dashboard simplifies complex data into an intuitive, high-level view of population trends and clinic metrics. By providing these “at-a-glance” insights, our tool empowers the entire care team to make faster, more informed decisions and refine their clinic strategy.
EndoTool Glucose Management System: As a pivotal step in advancing comprehensive inpatient and outpatient diabetes care, Glooko acquired Monarch Medical Technologies and its EndoTool Glucose Management System. The leading patient-specific inpatient insulin-dosing software, available only in the U.S., supports safer, more consistent glycemic management.
Meet with Team Glooko at ATTD 2026
Whether looking to reduce glycemic risk in the hospital or manage a large diabetes patient population in a clinic, find out why healthcare leaders choose Glooko for enterprise-wide, coordinated, data-driven care by visiting our booth or scheduling a demo.
EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company. EndoTool is an FDA-cleared Class II medical device indicated for inpatient use as described in its Instructions for Use. Glooko’s diabetes management platform and EndoTool are currently independent solutions. Patient-specific refers to EndoTool’s ability to use available patient information within the hospital’s electronic medical record to provide individualized insulin dosing recommendations. Recommendations are intended to assist, not replace, clinical judgment. All treatment decisions remain the responsibility of the licensed healthcare provider.